Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 242 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pediatric Brain Tumors Clear all

Conditions: Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor, Ependymoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Primary CNS Tumor
Interventions: Indoximod, Temozolomide, Conformal Radiation, Cyclophosphamide, Etoposide; Drug · Radiation
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 3 Years to 21 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 5
States / cities: Aurora, Colorado • Orlando, Florida • Atlanta, Georgia + 2 more

Conditions: Solid Tumors, Primary Brain Tumors
Interventions: Vincristine, Irinotecan, Temozolomide, Metformin; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 1 Year to 18 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 14
States / cities: Hartford, Connecticut • Wilmington, Delaware • Gainesville, Florida + 10 more

Conditions: Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
Interventions: Gemcitabine, ribociclib, sonidegib, trametinib, filgrastim; Drug · Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year to 39 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Primary Brain Tumor
Interventions: Captain's Log Computer Program; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 9 Years to 17 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
Interventions: 9-ING-41, Irinotecan, Temozolomide, Cyclophosphamide, Topotecan; Drug
Lead sponsor: Actuate Therapeutics Inc.; Industry
Eligibility: Up to 22 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Aurora, Colorado • Chicago, Illinois + 6 more

Conditions: Glioma, Brain Cancer, Brain Tumor, Glioblastoma Multiforme, High Grade Glioma
Interventions: Dendritic Cell Vaccine, Tumor Lysate, Imiquimod, Leukapheresis; Biological · Other · Procedure
Lead sponsor: Edward Ziga; Other
Eligibility: 1 Year to 29 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: lomustine, temozolomide; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Lymphoma, Childhood Lymphoma, Solid Tumor, Childhood Solid Tumor, Neuroblastoma, Ewing Sarcoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Medulloblastoma, Germ Cell Tumor, Wilms Tumor, Brain Neoplasms, Medulloblastoma, Childhood, Neuroectodermal Tumors, Primitive
Interventions: Genistein, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 1 Year to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Pediatric ALL, Epilepsy
Interventions: wearable EEG sensor; Device
Lead sponsor: Northwestern University; Other
Eligibility: 1 Day to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diffuse Intrinsic Pontine Glioma, PNET, Ependymoma, Germinoma, Medulloblastoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Month to 21 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain Tumor, Low Grade Glioma, Astrocytoma, Ependymoma, Ganglioglioma
Interventions: Proton radiotherapy; Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 1 Year to 25 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Sarcoma, Pediatric Brain Tumors
Interventions: Not listed
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 0 Years to 26 Years
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Central Nervous System Tumor, Brain Tumor, Spinal Tumor
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 2 Years to 18 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Brain and Central Nervous System Tumors
Interventions: therapeutic autologous dendritic cells; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 1 Year to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
Interventions: Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG); Biological · Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 0 Years to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts

Conditions: Pediatric Brain Tumors
Interventions: Hyperpolarized Pyruvate; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 3 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Central Nervous System Tumors, Brain Tumors
Interventions: Radiation Therapy; Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 8 Months to 25 Years
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2022
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Pediatric Brain Tumor, Pediatric Spine Tumor
Interventions: pNANO Assessment; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 1 Year to 17 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Solid Tumors, CNS Tumors
Interventions: Entrectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 15
States / cities: La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Solid Tumor, Leukemia, Lymphoma, Brain Tumor
Interventions: IMPACT, ESO; Behavioral · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 0 Years to 18 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 3
States / cities: Cincinnati, Ohio • Dayton, Ohio • Oklahoma City, Oklahoma

Conditions: Medulloblastoma, Pontine Glioma, Ependymoma, Astrocytoma, PNET
Interventions: Temozolomide, ABT-888; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain Tumors, Non-CNS Malignancies
Interventions: Quality of Life surveys completed at specified timepoints; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 2 Years to 25 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Central Nervous System Tumors
Interventions: BLZ-100; Drug
Lead sponsor: Blaze Bioscience Inc.; Industry
Eligibility: 1 Month to 30 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Central Nervous System Tumor, Pediatric, Neuroblastoma
Interventions: temozolomide, thalidomide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Up to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Metformin in Children With Relapsed or Refractory Solid Tumors

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Computerized Cognitive Training for Childhood Cancer Survivors

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors

Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

Pediatric EEG Monitoring

Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation

Pediatric Radiation Therapy Registry

Medical Marijuana in the Pediatric Central Nervous System Tumor Population

Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors

A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects

Evaluation of the Neurologic Assessment in Pediatric Neuro-Oncology (pNANO)

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Illness Management and Parental Adjustment to Cancer Treatment

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies

Study of BLZ-100 in Pediatric Subjects With CNS Tumors

Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma